The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated and revised their 2013 evidence-based guideline:
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
The "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors" continues to set evidence-based standards for clinical molecular testing of non-small cell lung cancers (NSCLC) that effectively guides targeted therapy and treatment.
Philip T. Cagle, MD, on behalf of CAP
Yasushi Yatabe, MD, PhD, on behalf of IASLC
Neal Lindeman, MD on behalf of AMP
This guideline was endorsed by the American Society of Clinical Oncology on February 5, 2018
Full JTO Article
Molecular Testing Guideline Resources
Molecular Testing Guideline Video for Physicians
Molecular Testing Guideline Video for Patients
The Pathology Committee is very involved in the creation of testing resources and educational content, from the new Immunohistochemistry Atlas to ILCN articles about timely and nuanced topics relevant to pathology. Led by Dr. Keith Kerr, the committee boasts a long timeline of milestone achievements.